Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lartruvo Phase III Fail Rocks Lilly Oncology Plans

Executive Summary

It looks like the end for Latruvo after a late-stage trial in soft tissue sarcoma patients did not confirm the overall survival benefit seen in the Phase II study that saw the Lilly drug get a speedy approval from the FDA and the EMA in 2016.


Related Content

What Late-Breakers To Look Out For At ASCO 2019
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
Lilly Has A Couple Of Controversies To Cover During Earnings Call
Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs
Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals
Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential
Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca
Lilly/Loxo Deal Came Together Quickly
Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK
Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts